論文 - 益崎　裕章

代謝的に健康な肥満者と不健康な肥満者を特徴付ける腸内細菌と血清代謝物

上間 次己, 山城 清人, 仲村 武裕, 上原 盛幸, 本間 健一郎, 岡本 士毅, 益崎 裕章

糖尿病 ( (一社)日本糖尿病学会 )  66 ( 5 ) 402 - 402   2023年05月

掲載種別: 研究論文（その他学術会議資料等）

腸脳連関とメトホルミン作用

益崎 裕章, 上間 次己, 中山 良朗, 山城 清人, 照屋 太輝, 本間 健一郎, 岡本 士毅

糖尿病 ( (一社)日本糖尿病学会 )  66 ( 5 ) 373 - 374   2023年05月

掲載種別: 研究論文（その他学術会議資料等）

糖尿病・肥満症の脳 中枢神経系におけるエネルギー代謝制御と精神疾患

岡本 士毅, 島袋 充生, 箕越 靖彦, 益崎 裕章

糖尿病 ( (一社)日本糖尿病学会 )  66 ( 5 ) 390 - 390   2023年05月

掲載種別: 研究論文（その他学術会議資料等）

特集 プライマリケア医に必要な情報をまるっと整理 くすりの使い方便利帳 第6章　代謝系に作用する薬剤 [糖尿病治療薬] チアゾリジン誘導体

本間 健一郎, 益崎 裕章

内科 ( 南江堂 )  131 ( 4 ) 806 - 810   2023年04月

掲載種別: 研究論文（学術雑誌）

• この論文にアクセスする

  DOI
• 関連情報を調べる
  CiNii Research

Effect of dapagliflozin on 24-hour glycemic variables in Japanese patients with type 2 diabetes mellitus receiving basal insulin supported oral therapy (DBOT): a multicenter, randomized, open-label, parallel-group study.

Kudo A, Machii N, Ono T, Saito H, Oshiro Y, Takahashi R, Oshiro K, Taneda Y, Higa M, Nakachi K, Yagi S, Masuzaki H, Sata M, Shimabukuro M

BMJ open diabetes research & care ( BMJ Open Diabetes Research and Care )  11 ( 2 )   2023年04月 [ 査読有り ]

掲載種別: 研究論文（学術雑誌）

　概要を見る

INTRODUCTION: This study aimed to evaluate the impacts of dapagliflozin on 24-hour glucose variability and diabetes-related biochemical variables in Japanese patients with type 2 diabetes who had received basal insulin supported oral therapy (BOT). RESEARCH DESIGN AND METHODS: Changes in mean daily blood glucose level before and after 48-72 hours of add-on or no add-on of dapagliflozin (primary end point) and diabetes-related biochemical variables and major safety variables during the 12 weeks (secondary end point) were evaluated in the multicenter, randomized, two-arm, open-label, parallel-group comparison study. RESULTS: Among 36 participants, 18 were included in the no add-on group and 18 were included in the dapagliflozin add-on group. Age, gender, and body mass index were comparable between the groups. There were no changes in continuous glucose monitoring metrics in the no add-on group. In the dapagliflozin add-on group, mean glucose (183-156 mg/dL, p=0.001), maximum glucose (300-253, p<0.01), and SD glucose (57-45, p<0.05) decreased. Time in range increased (p<0.05), while time above the range decreased in the dapagliflozin add-on group but not in the no add-on group. After 12-week treatment with dapagliflozin add-on, 8-hydroxy-2'-deoxyguanosine (8OHdG), as well as hemoglobin A1c (HbA1c), decreased. CONCLUSIONS: This study showed that the mean daily blood glucose and other daily glucose profiles were amended after 48-72 hours of dapagliflozin add-on in Japanese patients with type 2 diabetes who received BOT. The diabetes-related biochemical variables such as HbA1c and urinary 8OHdG were also obtained during the 12 weeks of dapagliflozin add-on without major adverse events. A preferable 24-hour glucose profile in 'time in ranges' and an improvement in reactive oxygen species by dapagliflozin warrant us to evaluate these benefits in larger clinical studies. TRIAL REGISTRATION NUMBER: UMIN000019457.

• この論文にアクセスする

  DOI
• 関連情報を調べる
  PubMed

マウス脂肪肝形成に対する玄米由来機能成分γ-オリザノールの抑制メカニズム

岡本 士毅, 島袋 省吾, 島袋 康貴, 照屋 太輝, 根本 雄飛, 玉城 啓太, 上間 次己, 本間 健一郎, 島袋 充生, 益崎 裕章

糖尿病 ( (一社)日本糖尿病学会 )  66 ( Suppl.1 ) S - 301   2023年04月

掲載種別: 研究論文（その他学術会議資料等）

玄米由来機能成分γ-オリザノール含有ナノ粒子製剤による老齢マウスの認知機能改善効果及び海馬における神経新生促進効果

照屋 太輝, 島袋 康貴, 上間 次己, 本間 健一郎, 根本 雄飛, 玉城 啓太, 岡本 士毅, 益崎 裕章

糖尿病 ( (一社)日本糖尿病学会 )  66 ( Suppl.1 ) S - 194   2023年04月

掲載種別: 研究論文（その他学術会議資料等）

玄米由来機能成分γ-オリザノール含有ナノ粒子製剤による老齢マウスの認知機能改善効果及び海馬における神経新生促進効果

照屋 太輝, 島袋 康貴, 上間 次己, 本間 健一郎, 根本 雄飛, 玉城 啓太, 岡本 士毅, 益崎 裕章

糖尿病 ( (一社)日本糖尿病学会 )  66 ( Suppl.1 ) S - 194   2023年04月

掲載種別: 研究論文（その他学術会議資料等）

マウス脂肪肝形成に対する玄米由来機能成分γ-オリザノールの抑制メカニズム

岡本 士毅, 島袋 省吾, 島袋 康貴, 照屋 太輝, 根本 雄飛, 玉城 啓太, 上間 次己, 本間 健一郎, 島袋 充生, 益崎 裕章

糖尿病 ( (一社)日本糖尿病学会 )  66 ( Suppl.1 ) S - 301   2023年04月

掲載種別: 研究論文（その他学術会議資料等）

A Comprehensive Study of the Immunophenotype and its Clinicopathological Significance in Adult T-cell Leukemia/Lymphoma.

Tamaki T, Karube K, Sakihama S, Tsuruta Y, Awazawa R, Hayashi M, Nakada N, Matsumoto H, Yagi N, Ohshiro K, Nakazato I, Kitamura S, Nishi Y, Miyagi T, Yamaguchi S, Nakachi S, Morishima S, Masuzaki H, Takahashi K, Fukushima T, Wada N

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc ( Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc )  36 ( 8 ) 100169 - 100169   2023年03月 [ 査読有り ]

掲載種別: 研究論文（学術雑誌）

　概要を見る

Adult T-cell leukemia/lymphoma (ATLL) is a mature T-cell tumor caused by human T-lymphotropic virus type 1 (HTLV-1). The typical ATLL immunophenotypes are described in the 2017 World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues (positive: CD2, CD3, CD5, CD4, and CD25; negative: CD7, CD8, and cytotoxic markers; and partially positive: CD30, CCR4, and FOXP3). However, limited studies are available on the expression of these markers, and their mutual relationship remains unknown. Furthermore, the expression status of novel markers associated with T-cell lymphomas, including Th1 markers (T-bet and CXCR3), Th2 markers (GATA3 and CCR4), T follicular helper markers (BCL6, PD1, and ICOS), and T-cell receptor (TCR) markers, and their clinicopathologic significance is unclear. In this study, we performed >20 immunohistochemical stains in 117 ATLL cases to determine the comprehensive immunophenotypic profile of ATLL, which were compared on the basis of clinicopathologic factors, including morphologic variants (pleomorphic vs anaplastic), biopsy locations, treatments, Shimoyama classification-based clinical subtype, and overall survival. CD3+/CD4+/CD25+/CCR4+ was considered a typical immunophenotype of ATLL, but approximately 20% of cases did not conform to this pattern. Simultaneously, the following new findings were obtained: (1) most cases were negative for TCR-β and TCR-δ (104 cases, 88.9%), indicating the usefulness of negative conversion of TCR expression to provide differentiation from other T-cell tumors; (2) the positivity of CD30 and CD15 and the negativity of FOXP3 and CD3 were significantly associated with anaplastic morphology; and (3) atypical cases, such as T follicular helper marker-positive (12 cases, 10.3%) and cytotoxic molecule-positive cases (3 cases, 2.6%), were identified. No single markers could predict the overall survival among patients with acute/lymphoma subtypes of ATLL. The results of this study illustrate the diversity of ATLL phenotypes. In T-cell tumors occurring in HTLV-1 carriers, the possibility of ATLL should not be eliminated even when the tumor exhibits an atypical phenotype, and the confirmation of HTLV-1 in the tissue is recommended.

• この論文にアクセスする

  DOI
• 関連情報を調べる
  PubMed

代謝的に健康な肥満者と不健康な肥満者を特徴付ける腸示細菌と血清代謝物

上間 次己, 山城 清人, 仲村 武裕, 上原 盛幸, 本間 健一郎, 岡本 士毅, 益崎 裕章

日本内分泌学会雑誌 ( (一社)日本内分泌学会 )  98 ( 5 ) 1568 - 1568   2023年03月

掲載種別: 研究論文（その他学術会議資料等）

代謝的に健康な肥満者と不健康な肥満者を特徴付ける腸内細菌と血清代謝物

上間 次己, 山城 清人, 仲村 武裕, 上原 盛幸, 本間 健一郎, 岡本 士毅, 益崎 裕章

日本内分泌学会雑誌 ( (一社)日本内分泌学会 )  98 ( 5 ) 1568 - 1568   2023年03月

掲載種別: 研究論文（その他学術会議資料等）

Markers for obese and non-obese Type 2 diabetes identified using whole blood metabolomics.

Teruya T, Sunagawa S, Mori A, Masuzaki H, Yanagida M

Scientific reports ( Scientific Reports )  13 ( 1 ) 2460   2023年02月 [ 査読有り ]

掲載種別: 研究論文（学術雑誌）

• この論文にアクセスする

  DOI
• 関連情報を調べる
  PubMed

Fatal acquired coagulation factor V deficiency after hepatectomy for advanced hepatocellular carcinoma as a possible immune checkpoint inhibitor-related adverse event: a case report.

Arakaki S, Ono S, Kawamata F, Ishino S, Uesato Y, Nakajima T, Nishi Y, Morishima S, Arakaki S, Maeshiro T, Souri M, Ichinose A, Masuzaki H, Takatsuki M

Surgical case reports ( SpringerOpen )  9 ( 1 ) 16 - 7   2023年02月 [ 査読有り ]

掲載種別: 研究論文（学術雑誌）

　概要を見る

Background Atezolizumab plus bevacizumab therapy was recently introduced as the first line for unresectable advanced hepatocellular carcinoma (HCC), but immune-related adverse events (IrAEs) due to atezolizumab are a great concern. Here, we report the case of a patient who developed fatal acquired coagulation factor deficiency after hepatectomy for HCC, treated with atezolizumab and bevacizumab before surgery. Case presentation A 70-year-old man received right trisegmentectomy of the liver with hepaticojejunostomy for advanced HCC with bile duct invasion, after atezolizumab and bevacizumab therapy. The patient suffered the sudden onset of severe multiple coagulation factor deficiency (II, V, VII, VIII, IX, X, XI and XII) immediately following reoperation for anastomotic leakage of hepaticojejunostomy, 7 days after hepatectomy. The coagulation factor deficiency did not reverse even with intensive treatment, and the patient died of uncontrollable bleeding 32 days after hepatectomy. An IrAE due to atezolizumab was suspected because the patient had developed the possible IrAE of enthesitis of the right gastrocnemius muscle before surgery, and specific inhibitors against factor V and anti-factor V autoantibodies were detected, leading to an ultimate diagnosis of autoimmune FV/5 deficiency (AiF5D). Conclusion Severe acquired coagulopathy should be recognized as a possible life-threatening IrAE when using atezolizumab and bevacizumab for HCC.

• この論文にアクセスする

  DOI
• 関連情報を調べる
  PubMed CiNii Research

「肥満する脳」と「肥満した脳」 糖尿病・肥満症の病態における新しい脳の役割

岡本 士毅, 島袋 充生, 箕越 靖彦, 益崎 裕章

糖尿病 ( (一社)日本糖尿病学会 )  66 ( 1 ) 42 - 42   2023年01月

掲載種別: 研究論文（その他学術会議資料等）

A nutritional assessment tool, GNRI, predicts sarcopenia and its components in type 2 diabetes mellitus: A Japanese cross-sectional study.

Shiroma K, Tanabe H, Takiguchi Y, Yamaguchi M, Sato M, Saito H, Tanaka K, Masuzaki H, Kazama JJ, Shimabukuro M

Frontiers in nutrition ( Frontiers in Nutrition )  10   1087471 - 1087471   2023年 [ 査読有り ]

掲載種別: 研究論文（学術雑誌）

　概要を見る

BACKGROUND: There are few reports evaluating the relationship between undernutrition and the risk of sarcopenia in type 2 diabetes mellitus (T2DM) patients. OBJECTIVE: We investigated whether undernutritional status assessed by the geriatric nutritional risk index (GNRI) and controlling nutritional status (CONUT) were associated with the diagnosis of sarcopenia. METHODS: This was a cross-sectional study of Japanese individuals with T2DM. Univariate or multivariate logistic regression analysis was performed to assess the association of albumin, GNRI, and CONUT with the diagnosis of sarcopenia. The optimal cut-off values were determined by the receiver operating characteristic (ROC) curve to diagnose sarcopenia. RESULTS: In 479 individuals with T2DM, the median age was 71 years [IQR 62, 77], including 264 (55.1%) men. The median duration of diabetes was 17 [11, 23] years. The prevalence of sarcopenia was 41 (8.6%) in all, 21/264 (8.0%) in men, and 20/215 (9.3%) in women. AUCs were ordered from largest to smallest as follows: GNRI > albumin > CONUT. The cut-off values of GNRI were associated with a diagnosis of sarcopenia in multiple logistic regression analysis (odds ratio 9.91, 95% confidential interval 5.72-17.2), P < 0.001. The superiority of GNRI as compared to albumin and CONUT for detecting sarcopenia was also observed in the subclasses of men, women, body mass index (BMI) < 22, and BMI ≥ 22. CONCLUSIONS: Results showed that GNRI shows a superior diagnostic power in the diagnosis of sarcopenia. Additionally, its optimal cut-off points were useful overall or in the subclasses. Future large and prospective studies will be required to confirm the utility of the GNRI cut-off for undernutrition individuals at risk for sarcopenia.

• この論文にアクセスする

  DOI
• 関連情報を調べる
  PubMed CiNii Research

摂食行動制御を司る新規神経回路と肥満における変化

岡本 士毅, 益崎 裕章

実験医学　増刊「神経系を介した臓器ネットワーク―代謝、摂食、免疫、運動、生体リズム、冬眠」   41   115   2023年

掲載種別: 研究論文（学術雑誌）

• 関連情報を調べる
  CiNii Research

食事からみた先制医療の実践

益崎 裕章, 岡本 士毅

糖尿病・内分泌代謝内科   57   352 - 359   2023年

掲載種別: 研究論文（学術雑誌）

• 関連情報を調べる
  CiNii Research

超難治性血液がんの糖代謝特性に注目した糖尿病治療薬SGLT2阻害剤の抗腫瘍効果の発見

岡本 士毅, 益崎 裕章

細胞   55   65   2023年

掲載種別: 研究論文（学術雑誌）

• 関連情報を調べる
  CiNii Research

腸脳力を活かしたQOL 向上アプローチ：運動欲求・身体活動パフォーマンスに影響する腸内細菌の新知見

益崎 裕章, 岡本 士毅

特集/腸内フローラのバランス異常と疾患との関わり　アロスエルゴン   3   2023年

掲載種別: 研究論文（学術雑誌）

• 関連情報を調べる
  CiNii Research